Corrigendum to “Chemotherapeutic Drugs and Mitochondrial Dysfunction: Focus on Doxorubicin, Trastuzumab, and Sunitinib”

Detalles Bibliográficos
Autores principales: Gorini, Stefania, De Angelis, Antonella, Berrino, Liberato, Malara, Natalia, Rosano, Giuseppe, Ferraro, Elisabetta
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Hindawi 2019
Materias:
Corrigendum
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6617926/
https://www.ncbi.nlm.nih.gov/pubmed/31346363
http://dx.doi.org/10.1155/2019/9601435
_version_ 1783433803845337088
author Gorini, Stefania
De Angelis, Antonella
Berrino, Liberato
Malara, Natalia
Rosano, Giuseppe
Ferraro, Elisabetta
author_facet Gorini, Stefania
De Angelis, Antonella
Berrino, Liberato
Malara, Natalia
Rosano, Giuseppe
Ferraro, Elisabetta
author_sort Gorini, Stefania
collection PubMed
description
format Online
Article
Text
id pubmed-6617926
institution National Center for Biotechnology Information
language English
publishDate 2019
publisher Hindawi
record_format MEDLINE/PubMed
spelling pubmed-66179262019-07-25 Corrigendum to “Chemotherapeutic Drugs and Mitochondrial Dysfunction: Focus on Doxorubicin, Trastuzumab, and Sunitinib” Gorini, Stefania De Angelis, Antonella Berrino, Liberato Malara, Natalia Rosano, Giuseppe Ferraro, Elisabetta Oxid Med Cell Longev Corrigendum Hindawi 2019-06-26 /pmc/articles/PMC6617926/ /pubmed/31346363 http://dx.doi.org/10.1155/2019/9601435 Text en Copyright © 2019 Stefania Gorini et al. http://creativecommons.org/licenses/by/4.0/ This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
spellingShingle Corrigendum
Gorini, Stefania
De Angelis, Antonella
Berrino, Liberato
Malara, Natalia
Rosano, Giuseppe
Ferraro, Elisabetta
Corrigendum to “Chemotherapeutic Drugs and Mitochondrial Dysfunction: Focus on Doxorubicin, Trastuzumab, and Sunitinib”
title Corrigendum to “Chemotherapeutic Drugs and Mitochondrial Dysfunction: Focus on Doxorubicin, Trastuzumab, and Sunitinib”
title_full Corrigendum to “Chemotherapeutic Drugs and Mitochondrial Dysfunction: Focus on Doxorubicin, Trastuzumab, and Sunitinib”
title_fullStr Corrigendum to “Chemotherapeutic Drugs and Mitochondrial Dysfunction: Focus on Doxorubicin, Trastuzumab, and Sunitinib”
title_full_unstemmed Corrigendum to “Chemotherapeutic Drugs and Mitochondrial Dysfunction: Focus on Doxorubicin, Trastuzumab, and Sunitinib”
title_short Corrigendum to “Chemotherapeutic Drugs and Mitochondrial Dysfunction: Focus on Doxorubicin, Trastuzumab, and Sunitinib”
title_sort corrigendum to “chemotherapeutic drugs and mitochondrial dysfunction: focus on doxorubicin, trastuzumab, and sunitinib”
topic Corrigendum
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6617926/
https://www.ncbi.nlm.nih.gov/pubmed/31346363
http://dx.doi.org/10.1155/2019/9601435
work_keys_str_mv AT gorinistefania corrigendumtochemotherapeuticdrugsandmitochondrialdysfunctionfocusondoxorubicintrastuzumabandsunitinib
AT deangelisantonella corrigendumtochemotherapeuticdrugsandmitochondrialdysfunctionfocusondoxorubicintrastuzumabandsunitinib
AT berrinoliberato corrigendumtochemotherapeuticdrugsandmitochondrialdysfunctionfocusondoxorubicintrastuzumabandsunitinib
AT malaranatalia corrigendumtochemotherapeuticdrugsandmitochondrialdysfunctionfocusondoxorubicintrastuzumabandsunitinib
AT rosanogiuseppe corrigendumtochemotherapeuticdrugsandmitochondrialdysfunctionfocusondoxorubicintrastuzumabandsunitinib
AT ferraroelisabetta corrigendumtochemotherapeuticdrugsandmitochondrialdysfunctionfocusondoxorubicintrastuzumabandsunitinib

Ejemplares similares